Characterizing cerebral toxoplasmosis in non‑HIV immunocompromised adults at Strasbourg University Hospital.
Official title: Retrospective Descriptive Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital From 2010 to 2023
Run by University Hospital, Strasbourg, France · NCT07299500 · Data updated 2026-11-12
This project will collect clinical information on adults with weakened immune systems (excluding HIV) who have cerebral toxoplasmosis to see which diagnostic methods, treatments, and preventive steps work best.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | February 2, 2025 |
| Main results expected | February 2026 |
| Study ends | February 25, 2026 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT07299500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18 or older) who are immunocompromised for any reason (e.g., solid organ or stem cell transplant, hematologic malignancy, cancer therapy, immunosuppressive drugs, autoimmune or primary/secondary immunodeficiency) and have at least one positive toxoplasmosis PCR and are HIV‑negative.
✕Probably not a fit
Patients who are HIV‑positive, have congenital toxoplasmosis, have isolated ocular toxoplasmosis while immunocompetent, or who refuse reuse of their data are not eligible and would not benefit from this cohort's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort will include adult, non‑HIV immunocompromised patients with at least one positive toxoplasmosis PCR identified at Strasbourg University Hospital. Investigators will compile clinical, imaging, laboratory, treatment, and outcome data to describe how the disease presents and is managed in these groups. The work aims to estimate how many patients are affected and to identify patterns that could inform diagnosis, therapy, and prevention outside the HIV setting. Patients who decline data reuse, those with congenital toxoplasmosis, or isolated ocular disease in immunocompetent people will be excluded from analysis.
Why it matters
Potential benefit: If successful, this could lead to clearer, evidence‑based guidance for diagnosing, treating, and preventing cerebral toxoplasmosis in non‑HIV immunocompromised patients.
How similar studies have gone: Management of cerebral toxoplasmosis is well established in people with HIV and there are recent recommendations for hematopoietic stem cell transplant recipients, but systematic data across other non‑HIV immunocompromised groups remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (≥18 years) * Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary). * At least one positive toxoplasmosis PCR test (regardless of tissue) Exclusion Criteria: * Subject who has expressed opposition to the reuse of their data for scientific research. * HIV positive * Congenital toxoplasmosis * Isolated ocular toxoplasmosis in immunocompetent individuals
Where it's running
-
Service d'immunologie clinique - Hôpitaux Universitaires de Strasbourg
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Mathilde HERBER, MD
- Email: mathilde.herber@chru-strasbourg.fr
- Phone: 33 3.69.55.13.99
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood microRNAs to distinguish schizophrenia, depression, and bipolar disorder in women with chronic toxoplasmosis
This project will test whether specific blood microRNA levels can help tell apart schizophrenia, major depression, and bipolar disorder in women with long-term Toxoplasma gondii infection.
-
Evaluating the prognosis of severe toxoplasmosis in ICU patients
This study looks at how well different treatments work for patients with severe toxoplasmosis in the ICU, especially those with weakened immune systems, to understand their chances of recovery.
-
Treating congenital toxoplasmosis with specific medications
This study is testing the best way to use a combination of medications to treat congenital toxoplasmosis in infants and also looks at treating infected fetuses in pregnant women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.